During the COVID-19 pandemic, a large pharmaceutical client required an alternative solution to on-site visits for an early access program. The solution had to be rapidly deployed to speed access to an investigational treatment for breast cancer patients. This was critically important due to their vulnerable health status and risk factors related to COVID-19.
In planning for the study, the client was receptive to incorporating novel approaches and quickly fostered a deep collaboration with the Evidera team to achieve study objectives as quickly as possible. Evidera’s dedicated study innovation team was positioned to help move the study forward quickly and worked with the client’s teams to drive rapid internal decisions.